Vigabatrin
Tuberous Sclerosis
Katarzyna KotulskaSmall moleculePhase 2/3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Tuberous Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Hospices Civils de Lyon | Phase 3 | BBB |
Sirolimus Katarzyna Kotulska | Phase 3 | BBB |
NPC-12G Nobelpharma | Phase 3 | BB |
Ganaxolone Marinus Pharmaceuticals | Phase 3 | BB |
NEUROTOP GRIN Therapeutics, Inc. | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Vigabatrin is also rated in:
benign partial epilepsy of infancy with complex partial seizuresDormant
B
Indicative · Phase 4
62 / 100
View asset →metabolic dysfunction-associated steatotic liver diseaseActive
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →